Core Viewpoint - Heng Rui Medicine (600276) has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors, with no similar drugs approved in the market currently [1] Group 1 - HRS-8364 tablets are a self-developed innovative anti-tumor drug by the company [1] - The drug is intended for the treatment of advanced solid tumors [1] - The total R&D investment for the HRS-8364 project has reached approximately 21.65 million yuan [1] Group 2 - The approval for clinical trials is a significant step, but the drug must still undergo clinical trials and regulatory reviews before it can be manufactured and marketed [1] - The drug development process is lengthy and involves uncertainties, which necessitates cautious decision-making by investors [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Product Development - HRS-8364 tablets are a self-developed innovative anti-tumor drug [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets [1] Group 2: Financial Investment - The total research and development investment for the HRS-8364 project has reached approximately 21.65 million yuan [1]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for the clinical trial of HRS-8364 tablets, an innovative anti-tumor drug developed by the company, aimed at treating advanced solid tumors [1] Group 1: Product Development - HRS-8364 tablets are a self-developed innovative anti-tumor drug [1] - The drug is intended for the treatment of advanced solid tumors [1] - Currently, there are no similar drugs approved for marketing domestically or internationally [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-8364 project has reached approximately 21.65 million yuan [1]

Core Viewpoint - Heng Rui Medicine (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4610 injection, an innovative anti-tumor drug developed by the company [1] Group 1 - SHR-4610 injection has shown good anti-tumor activity in preclinical animal models and is intended for the treatment of advanced solid tumors [1] - The total research and development investment for the SHR-4610 injection project has reached approximately 7.36 million yuan [1]